latest update:
[TrialBase DB]

trial summary · NCT07535905

Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients

Phase II Controlled Clinical Trial to Test Efficacy and Observe Longitudinal Effects of Tamoxifen for Testosterone Recovery in Medically Castrated Prostate Cancer Patients

Trial record from the TrialBase DB dataset, status RECRUITING, condition Hypogonadism, sponsored by University Health Network, Toronto. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07535905phase PHASE2enrollment 96start 2026-12-31

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Androgen deprivation therapy (ADT) is a cornerstone therapy in the treatment of curable prostate cancer (PCa). However, ADT often leads to a protracted testosterone recovery period in most men or absence of complete recovery in 10-25% of cases. The hypogonadal state has significant psychosocial and physical side effects. Therefore, limiting ADT effect's duration beyond the prescribed castration period is very compelling to patients and providers alike. Tamoxifen, a well-established selective estrogen receptor modulator, offers a novel and cost-effective approach to accelerate testosterone recovery in men with secondary hypogonadism. This project addresses a critical gap in global cancer care by evaluating Tamoxifen as a viable solution for reducing the burden of delayed testosterone recovery and its associated side effects, particularly in resource-limited settings.

Source record: https://clinicaltrials.gov/study/NCT07535905

Facts

registry idNCT07535905
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionHypogonadism
sponsorUniversity Health Network, Toronto
sponsor classOTHER
enrollment96
start date2026-12-31
primary completion2030-10
completion2030-10
results postednot reported

Conditions

  • Hypogonadism
  • Prostate Cancer

Interventions

  • Tamoxifen

Countries

  • Canada

Intervention types: DRUG

Work with this record